AKT1 and neoplasm: These data indicate that ABHD11-AS1 is a tumor promoter in TC, and it could be employed as a diagnostic and prognostic factor; moreover, its interplay with the PI3K/AKT pathway and glutamine transport paves the way for considering it as a therapeutic target.